PEPTOMYC SL Announces Treatment of First Patient with its Lead Compound OMO-103 in a Phase I/II Clinical Trial 06 / 05 / 21| Read More
Peptomyc Board of Directors appoints Giacomo Di Nepi as Chairman of the Board 07 / 01 / 21| Read More
Peptomyc receives 1.293.695,64 € from Spanish Mineco and European Commission joint fund 21 / 10 / 20| Read More
Peptomyc’s CEO Laura Soucek recognized as a Life Science Leader by Pharma Intelligence 09 / 06 / 20| Read More
